Daptomycin
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Daptomycin: From Gram-Positive Bacterial Infections to Osteoarthritis
One-Sentence Summary
Daptomycin is a cyclic lipopeptide antibiotic used to treat Gram-positive infections (e.g., complicated skin/skin-structure infections, S. aureus bacteraemia). TxGNN's top-ranked prediction is Osteoarthritis (score 99.86%), but the underlying literature almost entirely concerns treatment of infected joints (prosthetic joint infection, osteoarticular infection) rather than osteoarthritis itself — a likely knowledge-graph conflation. A lower-ranked but mechanistically far more credible signal, Rheumatoid Arthritis (rank 2, score 99.84%), is supported by two independent preclinical studies showing daptomycin suppresses inflammatory cytokines and NF-κB signalling in collagen-induced arthritis mice. No clinical trials exist for either indication; both remain at the hypothesis-generation stage.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not captured in this evidence pack (drug not marketed in this market); internationally approved for complicated skin/skin-structure infections and S. aureus bacteraemia, including right-sided infective endocarditis |
| Predicted New Indication | Osteoarthritis (top TxGNN rank; flagged as likely artifact — see below) |
| TxGNN Prediction Score | 99.86% (rank 2173) |
| Evidence Level | L4 (per source pack) — but literature is largely off-target (infection studies, not OA pathology) |
| Germany Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data was not available in this evidence pack (flagged as a High-severity data gap, DG002). Based on general pharmacology, daptomycin is a cyclic lipopeptide antibiotic that binds bacterial cell membranes in a calcium-dependent manner, causing membrane depolarization and rapid bactericidal killing of Gram-positive organisms. This mechanism has no established, direct link to the cartilage-degradation and joint-inflammation pathology of osteoarthritis.
Critically, when the top-ranked literature (10 papers) is examined, essentially all of it concerns daptomycin's antimicrobial use in infected joints — prosthetic joint infection, osteoarticular infection following S. aureus bacteraemia, and in vitro susceptibility testing — not osteoarthritis as a degenerative disease entity. This strongly suggests the knowledge graph has conflated "joint infection" and "osteoarthritis" as related joint-disease nodes, producing a high similarity score without genuine mechanistic relevance. We therefore treat the OA signal as likely spurious.
Signal Triage Note: Rheumatoid Arthritis Is the More Credible Candidate
A more scientifically defensible signal appears at rank 2 (Rheumatoid Arthritis, score 99.84%). Two independent, on-target preclinical studies (Tier 2) directly tested daptomycin in the collagen-induced arthritis (CIA) mouse model:
- PMID 39571268 (2025) — daptomycin suppressed inflammatory cytokines and NF-κB signalling, alleviating CIA in mice, proposed as a novel anti-inflammatory mechanism independent of its antibacterial activity.
- PMID 40923559 (2025) — a follow-up structure-optimization study synthesizing daptomycin-derived cyclic lipopeptides with improved anti-RA activity in the same model.
This represents a genuinely novel, mechanistically distinct hypothesis (immunomodulation via NF-κB inhibition) rather than a data-conflation artifact, and in our judgment merits a "Research Question" designation for further preclinical validation — well ahead of the top-ranked OA signal in terms of biological plausibility.
Clinical Trial Evidence
Currently no related clinical trials registered (neither for osteoarthritis nor for rheumatoid arthritis).
Literature Evidence
(Primary table below reflects predicted_indications[0] = Osteoarthritis, per evidence pack structure)
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 23519823 | 2013 | Cohort | Int Orthop | High-dose daptomycin + rifampicin in Gram-positive osteoarticular infections |
| 22511636 | 2012 | Cohort | J Antimicrob Chemother | Daptomycin for knee/hip periprosthetic joint infections |
| 26235888 | 2015 | Cohort | Int J Antimicrob Agents | High-dose daptomycin for complicated bone/joint and implant-associated infections |
| 17999973 | 2008 | Cohort | J Antimicrob Chemother | Daptomycin vs standard therapy for osteoarticular infection with S. aureus bacteraemia |
| 22854340 | 2012 | In vitro | J Antibiot | Antimicrobial susceptibility of staphylococci from prosthetic joint infections |
| 21477701 | 2010 | Registry/Cohort | Med Clin (Barc) | EU-CORE registry: real-world daptomycin use in Spain across Gram-positive infections |
| 32206362 | 2020 | Case Report | Case Rep Orthop | Corynebacterium septic arthritis misdiagnosed as osteoarthritis |
| 23312602 | 2013 | Cohort | Int J Antimicrob Agents | Survey of prosthetic joint infection management practices |
| 25650692 | 2015 | Cohort | Surg Infect | 10-year microbiologic profile of staphylococci in osteoarticular infections |
| 41853106 | 2026 | Case Report | ASM Case Rep | Corynebacterium propinquum septic arthritis, first synovial fluid isolation |
Note on Rheumatoid Arthritis (rank 2, alternative candidate):
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 39571268 | 2025 | Animal preclinical (CIA mouse) | Int Immunopharmacol | Daptomycin suppresses inflammatory cytokines and NF-κB pathway, alleviates collagen-induced arthritis |
| 40923559 | 2025 | Animal preclinical (CIA mouse) | J Med Chem | Daptomycin-derived cyclic lipopeptides with enhanced anti-RA activity in vitro/in vivo |
Germany Market Information
Daptomycin is not currently marketed in this jurisdiction (0 authorizations on file); no license records are available to summarize.
Safety Considerations
Please refer to the package insert for safety information. (No structured warnings, contraindications, or DDI data were available in this evidence pack — flagged as a Blocking data gap, DG001, that must be resolved before any S1 safety evaluation.)
Contextual note: one adverse-event case report in the evidence set (PMID 36693494) describes daptomycin-induced rhabdomyolysis complicated by acute gouty arthritis — this is a known safety signal (CPK elevation/myopathy) relevant to musculoskeletal monitoring, not a repurposing opportunity.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction (osteoarthritis) is not supported by mechanistically relevant evidence — the underlying literature addresses joint infection treatment, not osteoarthritis pathology, and no clinical trials exist. This is very likely a knowledge-graph conflation rather than a genuine repurposing signal.
To proceed, the following is needed:
- Resolve Blocking data gap DG001 (drug label warnings/contraindications) before any safety evaluation can begin
- Resolve High-severity data gap DG002 (confirmed mechanism of action) to support mechanistic rationale review
- Recommend opening a separate research track for Rheumatoid Arthritis (rank 2): commission or review additional preclinical replication of the CIA mouse model findings (PMID 39571268, 40923559) before considering any clinical-stage investment
- If pursuing RA further, obtain dose-response and toxicity data specific to the anti-inflammatory (non-antibacterial) mechanism, since this would represent off-label, immunomodulatory use distinct from daptomycin's approved antibacterial indications
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.